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The antiarrhythmic and antifibrillatory effects of fle-
cainide acetate during the early postinfarction period
were evaluated in a conscious canine model of sudden
cardiac death. Ventricular tachycardia remained induc-
ible early after infarction in eight of nine dogs receiving
an intravenous loading dose offtecainide (2.0 mg/kg body
weight) and seven of eight dogs receiving saline vehicle.
In both the drug and vehicle groups, there was no sig-
nificant change in the ventricular refractory period or
in the cycle length of the induced ventricular tachycar-
dia. With a maintenance intravenous infusion of fle-
cainide, 1.0 mg/kg per h for 4 hours, the subsequent
occurrence of acute posterolateral ischemia resulted in
the development of ventricular fibrillation and sudden
death in seven of eight flecainide-treated and eight of
eight vehicle-treated dogs.
In the continuing search for antiarrhythmic agents with greater
therapeutic efficacy and less toxicity. ftecainide acetate ap-
pears to be one of the most promising recently introduced
drugs (1-5). Previous clinical studies in the United States
and Europe (6-9) have demonstrated encouraging efficacy
in the reduction of the frequency of chronic, stable ven-
tricular ectopic complexes. In patients with documented
ventricular tachyarrhythmias, Reid et al. (10) reported an
89% rate of efficacy for the prevention of ventricular tachy-
cardia during Holter electrocardiographic monitoring, whereas
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Seven additional postinfarction dogs with nonindu-
cible tachycardia during pretreatment programmed
stimulation, and thereby considered to be at "low risk"
for the development of ischemic ventricular fibrillation,
were also given ftecainide in an intravenous loading and
maintenance dosing regimen. The subsequent occur-
rence of posterolateral ischemia resulted in the devel-
opment of ventricular fibrillation in three of these seven
dogs.
These findings suggest that ftecainide acetate may not
possess pharmacologic properties useful in managing
ventricular tachycardia or in preventing ischemic ven-
tricular fibrillation in the presence of recent myocardial
damage.
(J Am Coil Cardiol 1987;9:359-65)
Anderson et al. (I I , 12) reported a 60% success rate in the
suppression of ventricular tachycardia induction by pro-
grammed pacing techniques with flecainide. However, the
efficacy of flecainide in the prevention of ventricular tachy-
arrhythmias or sudden death, or both, in patients in the early
stages after myocardial infarction has not been evaluated
extensively. In the present study, we examined the efficacy
of ftecainide acetate on the electrical induction of ventricular
tachycardia and the occurrence of ischemic ventricular fi-
brillation during the early postmyocardial infarction period
in a conscious canine model of sudden death (13,14). The
essential experimental features of this model are illustrated
in Figure I.
Methods
Surgical preparation. The surgical preparation of dogs
for later electrophysiologic studies has been described pre-
viously in detail (\5,16). Briefly, anterior myocardial in-
0735-10'17/87/$3.50
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Figure 1. Consciouscanine modelof suddendeath. Anteriormyo-
cardial ischemic injury (broken lines) is produced by a 2 hour
occlusionof the left anterior descendingcoronary artery, followed
by reperfusion through a critical stenosis. An epicardial bipolar
electrode(A) is suturedto the leftatrialappendagefor atrialpacing.
A bipolar plunge electrode (B) is inserted into the interventricular
septum, adjacent to the site of coronary artery occlusion, for the
determinationof ventricularexcitation threshold, effective refrac-
tory period and for the delivery of programmed ventricular ex-
trastimuli. The bared tip of an insulatedsilver wire (C) is inserted
into the lumen of the proximal left circumflex coronaryartery, and
the wire is sutured onto the surface of the heart. Dogs are returned
to the laboratory for electrophysiologic study 4 to 7 days after
surgical preparation.
farction was produced by a 2 hour occlusion of the mid-left
anterior descending coronary artery, followed by reperfu-
sion in the presence of a critical stenosis at the site of the
previous occlusion. Instrumentation for subsequent studies
included indwelling arterial and venous cannulas, bipolar
plunge electrodes sutured to the left atrial appendage and
right ventricular outflow tract and a 30 gauge silver wire
electrode inserted into the lumen of the left circumflex coro-
nary artery (3 mm in contact with the endothelium), I cm
from its origin (Fig. I).
Programmed ventricular stimulation and electro-
physiologic testing. Electrophysiologic studies were per-
formed in 26 conscious, unsedated animals 4 to 7 (mean ±
5 SEM 6 ± I) days after infarction. Electrocardiographic
intervals and electrophysiologic variables were determined
immediately before ventricular stimulation. Programmed
stimulation was performed using I to 3 extrastimuli during
sinus rhythm and during atrial pacing (2.5 Hz), by methods
described previously (15,16). During the introduction of
single extrastimuli (S2), the basic S IS2 coupling interval
ranged from 350 ms to the point of ventricular refractoriness.
With double and triple extrastimuli, S2S3 and S2S3S4 inter-
vals ranged from 182 to 125 ms. The end point of stimulation
was the reproducible induction of ventricular tachycardia or
completion of the protocol.
Nonsustained ventricular tachycardia was defined as five
or more repetitive complexes that terminated spontaneously
within 30 seconds. Sustained ventricular tachycardia per-
sisted at least 30 seconds or, in the event of hemodynamic
compromise, required pacing techniques for termination. If
nonsustained ventricular tachycardia could be initiated re-
producibly, more aggressive attempts to induce sustained
tachycardia were not made. If induced ventricular tachy-
cardia at baseline degenerated rapidly to ventricular fibril-
lation, the animal was not resuscitated, to avoid the con-
founding influence of repeated and occasionally prolonged
resuscitative efforts on the outcome of subsequent investi-
gations. Two animals were excluded from the study because
they responded to pretreatment programmed stimulation with
ventricular fibrillation.
Ventricular excitation threshold and effective refractory
period were measured during atrial pacing (2.5 Hz). The
ventricular excitation threshold was defined as the minimal
voltage required to capture the ventricle with a single ex-
trastimulus of 4 ms duration delivered 300 ms after the R
wave of the lead II electrocardiogram. The ventricular ef-
fective refractory period was defined as the longest R to
stimulus interval at which a 2 x threshold stimulus (4 ms
duration) failed to capture the ventricle.
Conscious canine model of sudden coronary death:
ventricular fibrillation in response to ischemia at a site
distant from a previous myocardial infarction. After the
completion of posttreatment programmed ventricular stim-
ulation, an anodal current of 150 /LA was applied to the
intimal surface of the left circumflex coronary artery of drug-
and vehicle-treated postinfarction dogs by way of the intra-
coronary silver wire electrode. The lead II electrocardio-
gram was recorded directly onto a Grass polygraph or was
recorded at preset intervals by a programmable cardiocas-
sette recorder.
On completion of the experiment at 24 hours of electrical
stimulation or on the development of ischemic ventricular
fibrillation, the heart was excised, and thrombus mass within
the left circumflex coronary artery was determined after
removal by careful dissection. The heart was cut into I cm
thick transverse sections that were incubated in 0.5% tri-
phenyltetrazolium chloride in 0.01 M phosphate buffer (pH
7.4). Infarct size was quantitated gravimetrically with the
aid of the differential histochemical staining technique and
expressed as percent of total left ventricular mass.
Experimental protocol. Three groups of conscious
postmyocardial infarction dogs (n = 24) were entered into
the present study. The 17 dogs in groups I and II responded
to baseline pretreatment programmed ventricular stimulation
with nonsustained or sustained ventricular tachycardia, and
were randomized to treatment with saline vehicle (group I,
n = 8) or flecainide acetate (group II, n = 9). These 17
dogs were used to evaluate the efficacy of flecainide versus
vehicle to suppress the induction of ventricular tachycardia
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by programmed stimulation and to prevent the development
of ventricular fibrillation in response to ischemia at a site
remote from the previous infarction. Flecainide was ad-
ministeredas an intravenous loadingdose of 2.0 mg/kg body
weight over 20 minutes. Saline vehicle was administered in
matching volume. Posttreatment electrophysiologic moni-
toring and repeat programmed ventricular stimulation were
performed 20 minutes after the cessation of the saline and
f1ecainide loading doses in groups I and Il, respectively.
Maintenance infusions of flecainide, 1.0 mg/kg per h for 4
hours in group II. or saline solution in matching volume for
group I. were initiated immediately after posttreatment pro-
grammed stimulation and coincident with the initiation of
intracoronaryelectricalstimulation for the suddendeath pro-
tocol. One flecainide-treated dog in group (( was found at
postmortemexaminationto have an improperly placed intra-
coronary stimulating electrode. resulting in a total of eight
animals in both group I and group (( for the ischemic ven-
tricular fibrillation study.
Seven additional postinfarction dogs with no inducible
tachycardia on programmed ventricular stimulation (group
((I) also wereentered intothis study. Previous investigations
in this laboratory have shown that such dogs have an in-
herent low risk for the subsequentdevelopment of ischemic
ventricular fibrillation (14). The seven group 1Il dogs were
used to evaluate the potential for f1 ecainide to exacerbate
the responses to programmed ventricular stimulation or acute
posterolateral ischemia. All seven dogs were given flecain-
ide in the loading and maintenance regimens described for
dogs in group II.
Drug administration. Flecainide acetate (Riker Labo-
ratories) was administered as a loading dose of 2.0 mg/kg
in 20 ml of saline (0.9% wt/vol) vehicle. administered over
20 minutes. Maintenance infusions of f1ecainide. 1.0 mg/kg
per h for 4 hours, were administered in a total volume of
40 ml saline solution. A preliminary study in this laboratory
(17) has demonstrated that the administration of f1ecainide
in this regimen. as well as in a lower dose regimen with a
loading infusion of 1.0 mg/kg, rapidly achieves and main-
tains plasma f1ecainide concentrations of 800 to 1.200 ng/rnl
throughout the maintenance infusion.
Statistical analysis. For all evaluations, data are ex-
pressed as mean ± SEM. Pre- and posttreatment values
within a given treatment group were compared by a paired
Student's t test. Differences among treatment groups were
analyzed by unpaired Student's t test. For all comparisons.
a probability value of less than 0.05 was considered the
criterion for significance.
Results
Electrophysiologic responses (Table 1). The electro-
cardiographic and electrophysiologic responses of postin-
farction dogs with inducible ventricular tachycardia to ve-
hicle (group I. n = 8) and f1ecainide (group II, n = 9)
administration are summarized in Table I. Flecainide
administration did not alter sinus heart rate, electrocardio-
graphic QRS, QTc and QT intervals or the ventricular re-
fractory period. It prolonged the PR interval, increased the
ventricular excitation threshold and reduced the mean ar-
terial pressure. Vehicle administration did not alter heart
rate, blood pressure or electrocardiographic and electro-
physiologic variables. In the seven postinfarctiondogs with-
out inducible ventricular tachycardia (group Ill), f1ecainide
administration slightly increased the ventricular refractory
period and QTc and QT intervals, while reducing the mean
arterial pressure.
Table I. Electrocardiographic and Electrophysiologic Responses in 17 Postinfarction Dogs
Vehicle (group Il (n = 8) Fleca inide (group II) (n = 9)
Before After Before After
Heart rate 108 ± 8 103 ± 6 114 :!: III 115 ± 9
(beats/min)
Mean arterial 82 ± 3 82 ± 4 88 ± 7 78 ± 5*
pressure (rnrn Hg)
PR interval (rns) 118 ± I 121 ± 4 108 ± 6 123 ± 4*
QRS interva l (rns) 57 ± I 58 ± I 61 ± 3 6O± I
QTc interval 283 ± 10 274 ± 10 308 ± 9 305 ± 12
(ms)/(seco nd) lf!
Paced QT interval 199 ± I 204 ± 203 ± 9 207 ± 9
(ms)
Ventricular exci tation 2.0 ± 0.3 2.0 ± 0 .3 2.4 ± 0.7 2.5 ± 0.7*
threshold (V)
Ventricular effec tive 169 ± 8 159 ± I 149 ± 6 149 ± 4
refractor y period
(rns)
*p < 0 .05 . comparing values after versus before treatment with flecainide.
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Figure 2. Effects of the intravenous administration of saline ve-
hicle (groupI, left panel) or ftecainide acetate, 2.0 mg/kg (group
II. right panel), on the responses of postinfarction dogs to pro-
grammed ventricular stimulation. Eachsymbol represents onedog,
with the nature of the response of each dog to programmed stim-
ulation before (PRE) and after (POST) treatment listed on the Y
axis. During pretreatment testing, programmed ventricular stim-
ulation initiated nonsustained or sustained ventricular tachycardia
(VT) in all 17 animals in these two groups.
-,-- -,--
PRE POST
VEHICLE
(GROUP I)
-,-- -,--
PRE POST
FLECAINIDE
(GROUP II)
I I
1 sec
o MIN
90 MIN
Programmed electrical stimulation (Fig. 2, Table 2).
The responses of postinfarction dogs with inducible ven-
tricular tachycardia to programmed ventricular stimulation,
before and after treatment with saline vehicle (group I) and
f1ecainide (group II), are summarized in Figure 2 and Table
2. The size of the underlying anterior myocardial infarction
did not differ between the two groups. The administration
Table 2. Response of 17 Postinfarction Dogs to Programmed
Ventricular Stimulation
Figure 3. Programmed ventricular stimulation and ischemic ven-
tricular fibrillation in a conscious postinfarction dog. The intro-
duction of three ventricular extrastimuli initiates sustained ven-
tricular tachyarrhythmia before (A) and after (B) the intravenous
(IV)administration of 2.0 mg/kg of flecainide acetate. Ventricular
tachycardia cycle length was 172 and 239 ms before and afterdrug
administration, respectively. In panel C, an anodal currentof 150
/-LA wasapplied to the intimal surface of the left circumflex (LeX)
coronary artery at timeO. A 1.0mg/kg perh flecainide maintenance
infusion also was initiated at time O. At 82 minutes of current and
infusion, electrocardiographic manifestation of acute ischemia and
ventricular ectopic rhythm is apparent. At 90 minutes, ventricular
tachycardia degenerates into ventricular fibrillation. The depicted
electrocardiogram is lead II.
Number of dogs with
inducible ventricular
tachycardia after
treatment
Pretreatment ventricular
tachycardia cycle
length (rns)
Posttreatment
ventricular
tachycardia cycle
length (ms)
Number of dogs with
ventricular
tachycardia cycle
length prolongation
(>20%)
Underlying anterior
infarct size (% of left
ventricle)
Vehicle
(group I)
(n = 8)
7
189 ± 10
195 ± 12
22 ± 3%
Flecainide
(group II)
(n = 9)
8
160 ± 8
172 ± 12
26 ± 3%
of the loading dose of f1ecainide failed to prevent the in-
duction of ventricular tachyarrhythmia by programmed
stimulation in eight of the nine dogs tested (Fig. 3). After
flecainide, one group II dog with nonsustained tachycardia
during baseline had no inducible testing tachycardia, and a
second dog with sustained tachycardia during baseline test-
ing responded to posttreatment testing with only nonsus-
tained tachycardia. Although the cycle length of induced
ventricular tachycardia tended to lengthen in some animals
after f1ecainide treatment, this trend did not achieve statis-
tical significance, and only one f1ecainide-treated dog had
a prolongation of ventricular tachycardia cycle length of
more than 20%. In the vehicle control group, seven of eight
dogs tested responded with inducible ventricular tachycardia
after saline administration, with one animal responding to
pretreatment testing with a short nonsustained ventricular
tachycardia that was nonresponsive after treatment.
Group III animals, by definition, had no induction of
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ventricular tachycardia during baseline programmed stim-
ulation testing. After f1ecainide administration, six of the
seven group III dogs continued to have no inducible ar-
rhythmia, whereas one exhibited a reproducible nonsus-
tained tachyarrhythmia. This latter animal had a relatively
large (25% of total left ventricle) anterior myocardial in-
farction for this group.
Conscious canine model of sudden death (Table 3,
Fig. 4). Immediately after posttreatment programmed stim-
ulation, an anodal current of ISO JLA was applied to the
intimal surface of the left circumflex coronary artery in all
24 postinfarction dogs. The responses of the vehicle (group
1)- and f1ecainide group II-treated dogs to left circumflex
coronary stimulation are summarized in Table 3 and Figure
4. The anterior myocardial infarct size did not differ sig-
nificantly between these two groups.
All eight of the vehicle-treated group I dogs (inducible
ventricular tachycardia at baseline) died suddenly of ven-
tricular fi brillation that developed in response to ischemia
at a site remote from the infarct site. This fi nding is con-
sistent with the previously reported high incidence of isch-
emic ventricular fibrillation in unprotected postinfarction
dogs (13, 14). The mean time to ischemic arrhythmic death
in the vehicle group was 359 ± 70 minutes. In group II
(f1 ecainide, inducible ventricular tachycardia at baseline)
seven of the eight postinfarction dogs developed ventricular
fibrill ation during acute posterolateral ischemia, with a mean
time to ischemic ventricular fi brillation of 203 ± 88 minutes
(Fig. 4, Table 3). Five of these group II dogs developed
ventricular fibrill ation during the maintenance infusion. and
two deaths occurred after the cessation of f1ecainide infu-
sion. Figure 3 (lower panels) illustrates the development of
ischemic ventricular fibrillat ion in a flecainide-treated post-
infarction dog.
Seven flecainide-treated group III animals (no inducible
ventricular tachycardia at baseline testing) also were sub-
jected to ischemia at a site remote from the previous infarct
site. The underlying anterior myocardial infarct size in the
group III dogs was signifi cantly smaller than that found in
Table 3. Conscious Canine Model of Sudden Death
Number of dogs with
ventricular fibrillation in
response to ischemia
Time to ventricular
fi brillation (mi n)
Underlying anterior infarct
size (% of left
ventricle)
Left ci rcumflex thrombus
mass (rng)
Vehicle
(group Il
(n = 8)
8
359 :!:: 70
22 :!:: 3%
7 :!:: 3
Flecainide
(group II )
(n = 8)
7
208 ::':: 88
26 ::':: 3%
3 ::':: I
100
80
e
• FLECAINIDE (n =8)zs 60
• VEHICLE (n=8)sa:
:> 40(/)
'I/l ~20 • • • • •
4 8 12 16 20 24
HOURS AFTER ISCHEMIA
Figure 4. Survival rates for vehicle (group I)-treated and ftecain-
ide acetate (group II)-treated postinfarction dogs after the devel-
opment of posterolateral ischemia following left circumflex coro-
nary artery intimal injury .
group I and II animals (percent of total left ventricle: 10 ±
4% in group III versus 22 ± 3% and 26 ± 3% in groups
1and I\, respectively) (p < 0 .05). Three of the seven group
III animals developed ischemic ventricular fibrillation at the
time of posterolateral ischemia. with a mean time to isch-
emic death of 450 ± 204 minutes. Two of the three ar-
rhythmic deaths occurred very shortly after the cessation of
the ftecainide maintenance infusion; the third was a late
death.
Discussion
Clinical antiarrhythmic efficacy of ftecainide. Initial
animal and clinical investigations (1, 2.5- 10) of ftecainide
acetate have indicated a very promising clinical efficacy for
this new class Ie antiarrhythmic agent. Previous studies
have shown that flecainide is effective in terminating par-
oxysmal supraventricular tachycardia operating through either
dual atrioventricular nodalor extranodal accessory pathways
(18-20), in suppressing chronic stable ventricular ectopic
beats (7 ,8) and, in preliminary reports (9, 10), in preventing
the induction of ventricular tachycardia by programmed
stimulation in some patient groups. However, patients with
recent myocardial infarction and compromised left ventric-
ular function were not included in the previous studies. The
antiarrhythmic efficacy of flecainide in this high risk group
of patients with recent myocardial injury therefore remains
uncertain (2 1).
Experimental antiarrhythmic efficacy of ftecainide.
The conscious canine model of sudden death described in
this report has been shown to be a reliable preparation for
studying sudden death in the early postmyocardial infarction
period. with the animals responding to ischemia at a site
remote from a previous myocardial infarction with sudden
ventricular fibrillation (13-1 6). Animals with provokable
ventricular tachycardia by programmed ventricular stimu-
lation before the ischemic event generally possess a sizable
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myocardial infarct, constituting 18 to 25% of the left ven-
tricular mass, and respond to a subsequent ischemic insult
with a high incidence of ventricular fibrillation (13,14).
However, postinfarction animals without provokable ven-
tricular tachycardia at baseline testing tend to have smaller
areas of myocardial infarction constituting approximately 5
to 10% of the left ventricle, and are at very low risk for
ventricular fibrillation or death in response to acute ischemia
( 14).
In a preliminary study in this laboratory, DiCarlo et al.
(17) reported that the administration of flecainide acetate to
anesthetized, open chest postinfarction dogs, in intravenous
loading and maintenance regimens identical to those used
in this study, achieved plasma drug concentrations similar
to those reported in previous clinical antiarrhythmic eval-
uations. DiCarlo et al. (17) reported that flecainide admin-
istration failed to alter ventricular fibrillation threshold val-
ues determined in normal, border zone and infarcted
myocardium, and failed to alter susceptibility to ventricular
tachycardia initiation by programmed stimulation in the
anesthetized dog. In the present investigation, flecainide
acetate displayed minimal efficacy in suppressing ventric-
ular tachycardia initiation by programmed pacing techniques
in the conscious dog, although there was a slight but insig-
nificant tendency toward a slowing of the rate of induced
tachycardia. Furthermore, flecainide acetate was ineffective
in preventing the development of ventricular fibrillation in
response to an ischemic episode superimposed on the pre-
vious myocardial infarction. In this regard, flecainide ace-
tate was far less efficacious in preventing ischemic ventric-
ular fibrillation than were the beta-adrenergic antagonist
nadolol (22), the beta-adrenergic antagonist/class III agent
d.l-sotalol (23) and the class III agents amiodarone (24),
bretylium (25) and d-sotalol (16) in this preparation. The
mean time to the occurrence of ischemic ventricular fibril-
lation was apparently shorter in the flecainide-treated dogs
compared with the control dogs, but this variable is mul-
tifactorial and does not necessarily reflect a proischemic or
profibrillatory tendency.
Previous studies by Wilber et al, (14) have demonstrated
that postinfarction dogs with no provokable ventricular
tachycardia at baseline programmed stimulation had a 90%
24 hour survival after the imposition of posterolateral isch-
emia. reflecting a very low vulnerability to ischemic ven-
tricular fibrillation. In our present study, three of seven dogs
(group III) without inducible ventricular tachycardia at base-
line testing died suddenly in response to acute posterolateral
ischemia after flecainide acetate treatment. Although the
small sample size of this group prohibits any definitive con-
clusion regarding a proarrhythmic potential, this finding is
consistent with the findings of previous studies (17,26) which
reported proarrhythmic and profibrillatory actions with fie-
cainide in dogs with recent myocardial infarction. It is im-
portant to note, however, that the purported proarrhythmic
actions of this agent in the postinfarction dog models may
be occurring at plasma concentrations in excess of those
required to control arrhythmias. particularly spontaneous
ectopic activity, in many patients. The potential proar-
rhythmic actions of flecainide additionally may be most
prevalent in the setting of recent, large myocardial infarction
(26).
Conclusions. During the early postinfarction period, in-
travenous flecainide acetate failed to prevent the provocation
of ventricular tachycardia by programmed ventricular stim-
ulation in the majority of postinfarction dogs tested. The
induced tachycardia cycle tended to lengthen after flecain-
ide, but the trend was not significant. Flecainide also was
ineffective in preventing the development of ventricular fi-
brillation in response to an acute ischemic event in the
postinfarction dogs. In a subgroup of animals that were
expected to be at a very low risk for ischemic ventricular
fibrillation, arrhythmic fatality occurred in three of seven
dogs subjected to posterolateral ischemia. Extrapolations
regarding drug efficacy from the preclinical animal evalu-
ation to the human situation always must be made with
caution. Based strictly on the experimental features of the
present animal model, our findings suggest that, during the
early recovery phase of acute myocardial infarction, fle-
cainide may not provide actions beneficial in the suppression
of ventricular tachycardia and ischemia-related ventricular
fibrillation. The potential for proarrhythmic effects with fle-
cain ide in the setting of recent myocardial infarction de-
serves clinical awareness and further investigation.
We thank Laura Sell for her expert preparation of this manuscript, and
gratefully acknowledge Riker Laboratories for supplying ftecainide acetate
for this study.
References
I. Hodess AB. Follansbee WP. Spear JF. Moore EN. Electrophysiolog-
ical effects of a new antiarrhythmic agent. fiecainide , on the intact
canine heart. 1 Cardiovasc Pharmacol 1979;1:427-39.
2. Anderson Jl., Stewart JR. Crevey Bl. A proposal for the clinical use
of flecainide, Am 1 Cardiol 1984;53:112B-9B.
3. Estes NAM. Garan H. Ruskin IN. Electrophysiologic properties of
ftecainide acetate. Am J Cardiol 1984;53:26B-9B.
4. Morganroth J. Horowitz LN. Flecainide: its proarrhythmic effect and
expected changes on the surface electrocardiogram. Am 1 Cardiel
1984;53;89B-94B.
5. Somani P. Antiarrhythmic effects of flecainide. Clin Pharmaco! Ther
1980:27:464-70.
6. Klempt HW. Walenta, Bender F. Die antiarrhythmische wirkung von
tlecainide bei ventrikularer cxtrasystolie. Herz Kreislauf 1980;12:358-62.
7. Anderson Jl.. Stewart lR, Perry BA. et al. Oral tlecainide acetate for
the treatment of ventricular arrhythmias. N Engl J Med 1981;305:473-7.
8. Woosley RL, Siddoway LA. Duff HJ. Roden DM. Flecainide dose-
response relations in stable ventricular arrhythmias. Am 1 Cardiol
I984;53;59B-658 .
9. Platia E, Estes M, Heine DL. et al. Flecainide: electrophysiologic and
lACC V,,1. 9. No. 2
February 19K7:356-65
KOU ET AL.
ANTIARRHYTHMIC EFFECTS OF FLECAINIDE
365
antiarrhythmic properties in refractory ventricular tachycardia. Am J
Cardiol 1985;55:956--62.
10. Reid PR. Griffith LSC. Platia EV. Ord SE. Evaluation "I' llecainide
acetate in the management of patients at high risk of sudden cardiac
death. Am J Cardiol 1984:53:108B-II B.
II . Anderson JL. Lutz JR. Allison SB. Electrophysiologic and antiar-
rhythmic effects of oral flecainide in patients with inducible ventricular
tachycardia. J Am Coil Cardiol 19H3;2:105-1 4.
12. Anderson JL. Experience with electrophysiulogically guided therapy
of ventricular tachycardia with lleeainide: summary of long-term "JI-
low-up, Am J Cardiol 1984;53:79B- 86B.
J 3. Patterson E. Holland K. Eller BT. Lucchesi BR. Ventricular fibril-
lation resulting from ischemia at a site remote from previous myo-
cardial infarction. Am J Cardiel 19li2:50:1414- 23.
14. Wilber OJ. Lynch JJ. Montgomery D. Lucchesi BR. Postinfarction
sudden death: significance of inducible ventricular tachycardia and
infarct size in a conscious canine model. Am Heart J 19li5:109:H-IH .
15. Lynch J. Montgomery D. Ventura A. Lucchesi B. Antiarrhythmicand
electrophysiologic effects of bepridil inchronically infarctedconscious
dogs. J Pharmacol Exp Ther 1985:234:72- HO.
16. Lynch JJ. Coskey LA. Montgomery DG. Lucchesi BR. Prevention
of ventricular fibrillation by dextrorotatory sotalol in a conscious ca-
nine model of sudden death, Am Heart J 19H5;109:949- 5X.
17. DiCarlo L. Lynch J. Montgomery D. Lucchesi B. Effect of llecainide
acetate on induced ventricular tachycardia and ventricular librillation
in dogs with recent myocardial infarction (abstr). Circulation
19li5;72(suppl 111 ):111 -225.
Iii. Hellestrand KJ. Nathan AW. Bexton RS. Spurrell RA. Camm AJ.
Cardiac electrophysiologic effects of Ilecainide acetate for paroxysmal
reentrant junctional tachycardia. Am J Cardiel 19113;51:770- 6.
19. Hellestrand KJ. Nathan AW. Bexton RS. Carnrn AJ. Electrophysio-
logic effects of tlecainide acetate on sinus node function. anomalous
atrioventricular connections and pacemaker threshold. Am J Cardiel
1984;53:30B- 8B.
20. Ward D. Jones S. Shinebournc E. The use of flecainide acetate for
control of junctional tachycardia in children (abstr). Circulation
I984:70(suppl 11):11-207.
21. Lal R. Chapman PD. Naccarrelli GV. et al. Short- and long-term
experience with ftecainide acetate in the management or refractory
life-threatening ventricular arrhythmias. J Am Coli Cardiel
19X5 :h:772- 4.
~~ . Patterson E. Lucchesi HR. Antifibrillatory actions or nadolol. J Phar-
macol Exp Ther I4X2:223:144- 52.
~ 3 . Patterson E. Lynch JJ. Lucchesi HR. Antiarrhythmic and antifibril-
latory actions of the beta-adrenergic receptor antagonist. d.l-sotalol.
J Phannacol Exp Ther 19X4:230:519- 26.
24. Patterson E. Eller HT. Abrams GD. Vasiliades J. Lucchesi BR. Ven-
tricular fibrillation in a conscious canine preparation or sudden coro-
nary death: prevention by short- and long-term arniodarone adminis-
tration. Circulation 19X3:6X:857- 64.
25. Holland K. Patterson E. Lucchesi HR. Prevention of ventricular fi-
brillation by hretylium in a consciouscanine model or sudden coronary
death. Am Heart J 1483:105:711- 7.
26. Zimmerman JM. Bigger J'T, Coromilas J. Flecainide acetate is ar-
rhythmogenic in a canine model of sustained ventricular tachycardia
(abstr). J Am Coil Cardiol 19H5:5:391.
